Peterson Wealth Services Has $655,000 Stock Holdings in Medtronic PLC $MDT

Peterson Wealth Services lowered its position in shares of Medtronic PLC (NYSE:MDT) by 67.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,874 shares of the medical technology company’s stock after selling 14,461 shares during the quarter. Peterson Wealth Services’ holdings in Medtronic were worth $655,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Riverbend Wealth Management LLC boosted its stake in shares of Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after buying an additional 107 shares during the period. Wynn Capital LLC increased its stake in Medtronic by 2.4% during the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after acquiring an additional 110 shares during the period. Meridian Investment Counsel Inc. raised its holdings in Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after acquiring an additional 110 shares in the last quarter. Saxony Capital Management LLC lifted its position in shares of Medtronic by 3.8% during the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after acquiring an additional 112 shares during the period. Finally, Cape Investment Advisory Inc. lifted its position in shares of Medtronic by 3.2% during the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after acquiring an additional 113 shares during the period. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

MDT has been the topic of a number of recent analyst reports. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. CICC Research began coverage on shares of Medtronic in a research report on Friday. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Trading Down 0.3%

NYSE MDT opened at $102.67 on Tuesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a market cap of $131.63 billion, a price-to-earnings ratio of 27.67, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71. The business’s fifty day moving average is $99.59 and its 200 day moving average is $95.82.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the firm earned $1.26 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).